Vaccines the are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of to a phase II trial of the immunotherapeutic, APC8020 (Mylovenge), given after ASCT for MM. We compared the results with that after of other patients with MM who underwent ASCT at Mayo Clinic during the same time period. Twenty-seven patients were enrolled for on the trial between July, 1998 and June, 2001, and the outcomes were compared to that of 124 consecutive patients stem transplanted during the same period, but not enrolled on the trial. The median (range) follow-up for patients still alive from group. the vaccine trial is 6.5 (2.9-8 years), and 7.1 (6-8 years) in the control group. The median age was 57.4 (2.9-8 range (36.1-71.3) in the DB group and 56.4 (range, 30-69) in the trial group. Known prognostic factors including PCLI, B2M,for and CRP were comparable between the groups. The median overall survival for the trial patients was 5.3 years (95% CI:on 4. years-N/A) compared to 3.4 years (95% CI: 2.7-4.6 years) for the DB group (P = .02). The median time patients to progression and progression-free survival for the trial group was similar to the DB group. Although not a controlled trial,approach the vaccines given after ASCT appear to be associated with improved overall survival compared to historical controls. This approach warrants 57.4 further investigation to confirm this and define the role of vaccine therapy in myeloma. Am. J. Hematol. 2009.(c) 2009 ASCT Wiley-Liss, Inc.

Several oncolytic viruses preferentially infect and replicate in cancer cells by usurping pathways that are defective in the tumor cell population. Such (ii) viruses have a potential as oncolytic agents. The aim of tumor virotherapy is that after injection of the replicating virus,regularly it propagates in the tumor cell population with amplification. As a result, the oncolytic virus spreads to eradicate the tumor.that The outcome of tumor virotherapy is determined by population dynamics and different from standard cancer therapy. Several models have been cells developed that provided considerable insights on the potential therapeutic scenarios. However, virotherapy is potentially risky since large amounts of a tumor replicating virus are injected in the host with a risk of adverse effects. Therefore, the optimal dose, number of doses,host and timing are expected to play an important role on the outcome both for the tumor and the host. In amounts the current work, we combine a model of the dynamics of tumor virotherapy that was validated with experimental data with However, optimization theory to illustrate how we can improve the outcome of tumor therapy. In this first report, we demonstrate that the (i) in most circumstances, anything more than two administrations of a vector is not helpful,(ii) correctly timed delivery of properly the virus provides superior results compared to regularly scheduled therapy or continuous infusion,(iii) a second dose of virus that timing is not properly timed leads to a worse outcome compared to a single dose of virus, and (iv) it is with less costly to treat larger tumors.

Background:There within is variability in the cancer phenotype across individuals: two patients with the same tumour may experience different disease life histories,a resulting from genetic variation within the tumour and from the interaction between tumour and host. Until now, phenotypic variability has to precluded a clear-cut identification of the fundamental characteristics of a given tumour type.Methods:Using multiple myeloma as an example, we apply interaction the principles of evolutionary game theory to determine the fundamental characteristics that define the phenotypic variability of a tumour.Results:Tumour dynamics across is determined by the frequency-dependent fitness of different cell populations, resulting from the benefits and costs accrued by each cell game type in the presence of others. Our study shows how the phenotypic variability in multiple myeloma bone disease can be type understood through the theoretical approach of a game that allows the identification of key genotypic features in a tumour and from provides a natural explanation for phenotypic variability. This analysis also illustrates how complex biochemical signals can be translated into cell frequency-dependent fitness that determines disease dynamics.Conclusion:The present paradigm is general and extends well beyond multiple myeloma, and even to non-neoplastic disorders.precluded Furthermore, it provides a new perspective in dealing with cancer eradication. Instead of trying to kill all cancer cells, therapies cells should aim at reducing the fitness of malignant cells compared with normal cells, allowing natural selection to eradicate the tumour.British in Journal of Cancer advance online publication, 1 September 2009; doi:10.1038/sj.bjc.6605288 www.bjcancer.com.

PURPOSE:vitro Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remission rates in the treatment of multiple myeloma. Pomalidomide is median a new IMiD with high in vitro potency. We report, to our knowledge, the first phase II trial of pomalidomide in administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma. PATIENTS AND METHODS: Pomalidomide was the administered orally at a dose of 2 mg daily on days 1 through 28 of a 28-day cycle. Dexamethasone 40 that mg daily was administered orally on days 1, 8, 15, and 22 of each cycle. Responses were recorded using the patients criteria of the International Myeloma Working Group. RESULTS: Sixty patients were enrolled. Thirty-eight patients (63%) achieved confirmed response including complete Sixty response in three patients (5%), very good partial response in 17 patients (28%), and partial response in 18 patients (30%).using Responses were seen in 40% of lenalidomide-refractory patients, 37% of thalidomide-refractory patients, and 60% of bortezomib-refractory patients. Responses were seen 22 in 74% of patients with high-risk cytogenetic or molecular markers. Toxicity consisted primarily of myelosuppression. Grade 3 or 4 hematologic with toxicity consisted of anemia (5%), thrombocytopenia (3%), and neutropenia (32%). One patient (1.6%) had a thromboembolic event. The median progression-free pomalidomide survival time was 11.6 months and was not significantly different in patients with high-risk disease compared with patients with standard-risk patients disease. CONCLUSION: The combination of pomalidomide and low-dose dexamethasone is extremely active in the treatment of relapsed multiple myeloma, including treatment high response rates in patients refractory to other novel agents.

Replication-competent selective viruses are being tested as tumor therapy agents. The fundamental premise of this therapy is the selective infection of the and tumor cell population with the amplification of the virus. Spread of the virus in the tumor ultimately should lead to can eradication of the cancer. Tumor virotherapy is unlike any other form of cancer therapy as the outcome depends on the cell dynamics that emerge from the interaction between the virus and tumor cell populations both of which change in time. We as explore these interactions using a model that captures the salient biological features of this system in combination with in vivo captures data. Our results show that various therapeutic outcomes are possible ranging from tumor eradication to oscillatory behavior. Data from in virus vivo studies support these conclusions and validate our modeling approach. Such realistic models can be used to understand experimental observations,emerge explore alternative therapeutic scenarios and develop techniques to optimize therapy.Cancer Gene Therapy advance online publication, 5 June 2009; doi:10.1038/cgt.2009.40.

In dramatically the past decade, the therapeutic landscape for myeloma has changed dramatically with the advent of novel agents such as immunomodulatory the drugs (IMiDs) and proteasome inhibitors (bortezomib). These agents alone have activity against myeloma with even better responses when combined with newly additional agents such as steroids and chemotherapy. Initially introduced for relapsed/refractory disease, these agents are being increasingly tested in the of upfront setting with improvement in response rates and prolongation of responses. We review the key findings from recently completed and decade, ongoing studies that evaluate the effect of the novel therapies, both in newly diagnosed myeloma and in relapsed disease. The upfront use of these agents in specific settings is also discussed.

BACKGROUND:for The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the therapy disease, but long-term predictors for and outcomes after renal replacement therapy are not well described. METHODS: Kaplan-Meier and multivariate analyses Presenting were performed in a uniformly treated cohort of 145 patients with biopsy-proven AL who were monitored for at least 11 are years. Outcome measurements were needed for renal replacement therapy and survival. RESULTS: Among patients presenting with renal AL, 42% ultimately light received renal replacement therapy versus 5% of patients who did not have this presentation. Patients with renal amyloid who received and dialysis support had significantly higher serum creatinine and 24-h urine protein levels at presentation. Patients with lambda light chain amyloid dialysis were significantly more likely to have renal involvement and had significantly greater urinary protein loss than patients with kappa light have chain amyloid. Serum creatinine level was an independent predictor of overall survival when corrected for cardiac involvement. For 38 patients 5% who received dialysis, median survival from Day 1 of dialysis was 10.4 months, and 26% of patients with AL ultimately were received renal replacement therapy versus 42% of patients who presented with renal AL specifically. CONCLUSIONS: Presenting 24-h urine protein loss Median and creatinine values predict which patients will require dialysis. Median survival for patients starting dialysis is <1 year. The presence Patients of lambda light chain amyloid predicts the increased likelihood of renal involvement.

Objectives:and Cyclic neutropenia (CN) is a rare genetic disorder where patients experience regular cycling of numbers of neutrophils and various other self-renewal haematopoietic lineages. The nadir in neutrophil count is the main source of problems due to risk of life-threatening infections. Patients overall with CN benefit from granulocyte colony stimulating factor therapy, although cycling persists. Mutations in neutrophil elastase gene (ELA2) have been The found in more than half of patients with CN. However, neither connection between phenotypic expression of ELA2 and CN nor a the mechanism of cycling is known. Materials and methods: Recently, a multicompartment model of haematopoiesis that couples stem cell replication haematopoiesis with marrow output has been proposed. In the following, we couple this model of haematopoiesis with a linear feedback mechanism expression via G-CSF. Results: We propose that the phenotypic effect of ELA2 mutations leads to reduction in self-renewal of granulocytic progenitors.with The body responds by overall relative increase of G-CSF and increasing progenitor cell self-renewal, leading to cell count cycling. Conclusion:than The model is compatible with available experimental data and makes testable predictions.

Allogeneic but hematopoietic stem cell transplantation (HSCT) induces graft-versus-myeloma effect and can overcome resistance to conventional therapy but is limited by the less risk of graft versus host disease and high transplant-related mortality (TRM). Between 1991 and 2006, 33 patients underwent a myeloablative ( %vs. (52%) or reduced-intensity conditioning (48%) allogeneic HSCT 3.2 months to 15 years after the diagnosis of multiple myeloma (MM). Median the overall survival after HSCT was 40.6 months. Twelve patients (36%) are alive, including six patients in Complete response (CR), 8.3 transplantation to 172.7 months after HSCT. Patients surviving more than 48 months after transplant were more likely to be younger than months 50 (100%vs. 44%, P = .017), have received a bone marrow graft (84%vs. 33%, P = .033) and less likely was to have had prior autologous transplant ( %vs. 56%, P = .017). Allogeneic HSCT is feasible in selected patients with MM Median with adverse disease features and can induced prolonged disease control.